A Form 4 filed on September 4, 2026, reports that Christopher P. Kiritsy, a director of Palvella Therapeutics, Inc. (NASDAQ:PVLA), exercised a stock option and sold common stock on September 2, 2026.
Key Highlights
- Option exercise: Kiritsy exercised a fully vested stock option (transaction code M) for 313 shares of common stock at an exercise price of $127.20 per share on September 2, 2026.
- Share sale: Kiritsy sold 313 shares of common stock (transaction code S) at $157 per share on the same date.
- Remaining ownership: Following the transactions, Kiritsy directly held 250 shares of common stock beneficially.
- Derivative securities: Following the option exercise, Kiritsy held 0 stock options with a $127.20 exercise price.
- Reverse split adjustment: All share and price figures reflect a 1-for-80 reverse stock split that became effective on April 23, 2024, according to the filing.
Kiritsy Option Exercise and Sale Details at Palvella Therapeutics
According to the filing, Christopher P. Kiritsy, identified as a director of Palvella Therapeutics, Inc., reported two transactions in common stock on September 2, 2026. First, he exercised a fully vested stock option to acquire 313 shares at an exercise price of $127.20 per share, recorded as an acquisition (A) under transaction code M. The filing notes that the stock option had an expiration date of September 20, 2026, and that the price of the derivative security in connection with the exercise was $0.
On the same date, the filing discloses that Kiritsy disposed of 313 shares of common stock (transaction code S) at a price of $157 per share. Following both transactions, Kiritsy's direct beneficial ownership of common stock stood at 250 shares, and his remaining position in the $127.20 stock option fell to 0, according to the filing.
The filing includes a footnote stating that "the reported number of shares has been adjusted to reflect the impact of the Issuer's 1-for-80 reverse stock split, which became effective on April 23, 2024." The Form 4 was signed by Kathleen A. McGowan as attorney-in-fact and filed on September 4, 2026.
What Was Disclosed
Director Christopher P. Kiritsy of Palvella Therapeutics disclosed the exercise of 313 stock option shares at $127.20 and the subsequent sale of 313 shares at $157 on September 2, 2026, leaving him with 250 shares directly held.




Please wait processing your request...